Alternatively, microenvironment reprogramming mechanisms from TNFRSF14 (6.9% vs 15.2%), S1PR2 (1.0% vs 5.8%), GNA13 (4.9% vs 11.8%), or EZH2 (4.9% vs 11.5%) mutations enriched in ndDLBCL (of which, the later three are notably absent in ABC subtype DLBCL) [55–59] may confer more sensitivity to standard immunochemotherapy. This evidence concerns the gene S1PR2 and diffuse large B-cell lymphoma.